Forest Road Acquisition Corp. FRX
Set alert
12.00 +12.00 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 450.00M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 4.70
- Inst. own
- 37.75%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 10.29
- 200-d avg
- 10.64
- 1y target
- 0.00
Key statistics
- Market cap
- 450.00M
- Enterprise value
- 449.27M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 730.43K
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 30.00M
- Short % of float
- 20.33%
- 50-day average
- 10.29
- 200-day average
- 10.64
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 16, 2021 | DA Davidson | init | — | Buy |
| Jun 7, 2021 | Loop Capital | init | — | Hold |
About Forest Road Acquisition Corp.
Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- spacroadone.com
News
- Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened
- Fennec Announces Results of Annual Meeting
- Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
- Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
- Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
- Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
- Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
- Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below Fifty Day Moving Average – Here’s What Happened
- Southpoint Capital Advisors Lp Sells 160,100 Shares of Fennec Pharmaceuticals (TSE:FRX) Stock
Your note
Sign in to keep a note on FRX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 3.60% | 1,079,196 | 10.92M | Mar 30, 2021 |
| Weiss Asset Management LP | 1.84% | 551,400 | 5.58M | Mar 30, 2021 |
| Linden Advisors LP | 1.64% | 493,499 | 4.99M | Mar 30, 2021 |
| DSAM Partners (London) Ltd | 1.64% | 492,283 | 4.98M | Mar 30, 2021 |
| Kepos Capital Lp | 1.60% | 480,000 | 4.86M | Mar 30, 2021 |
| Point72 Asset Management, L.P. | 1.53% | 459,882 | 4.65M | Mar 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Managed Portfolio Series- Friess Small Cap Growth Fd | 0.21% | 63,800 | 645.66K | Mar 30, 2021 |
| Highland Fds I-NexPoint Merger Arbitrage Fund | 0.13% | 40,000 | 404.80K | Mar 30, 2021 |
| Fidelity Convertible Securities Fund | 0.10% | 30,943 | 310.67K | Apr 29, 2021 |
| Fidelity Advisor Multi-Asset Income Fund | 0.04% | 12,000 | 120.48K | Apr 29, 2021 |